Press releases
- European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
- Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- Organon Announces Proposed $1.0 Billion Senior Notes Offering
- Organon Reports Results for the First Quarter Ended March 31, 2024
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
More ▼
Key statistics
On Wednesday, Organon & Co (OGN*:MEX) closed at 356.07, -2.36% below its 52-week high of 364.67, set on Jul 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 356.07 |
---|---|
High | 356.07 |
Low | 356.07 |
Bid | 339.00 |
Offer | 379.97 |
Previous close | 356.07 |
Average volume | 44.00 |
---|---|
Shares outstanding | 257.17m |
Free float | 256.77m |
P/E (TTM) | 5.15 |
Market cap | 5.40bn USD |
EPS (TTM) | 4.08 USD |
Annual div (ADY) | 18.79 MXN |
---|---|
Annual div yield (ADY) | 5.28% |
Div ex-date | May 10 2024 |
Div pay-date | Jun 13 2024 |
Data delayed at least 20 minutes, as of May 22 2024 14:02 BST.
More ▼